2689 related articles for article (PubMed ID: 21535989)
21. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
Lee SE; Min CK; Yahng SA; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Eur J Haematol; 2011 Jan; 86(1):83-6. PubMed ID: 20946110
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity.
Martin TJ; Ng KW
J Cell Biochem; 1994 Nov; 56(3):357-66. PubMed ID: 7876329
[TBL] [Abstract][Full Text] [Related]
23. Parathyroid hormone temporal effects on bone formation and resorption.
Kroll MH
Bull Math Biol; 2000 Jan; 62(1):163-88. PubMed ID: 10824426
[TBL] [Abstract][Full Text] [Related]
24. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
25. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
26. The cellular actions of interleukin-11 on bone resorption in vitro.
Hill PA; Tumber A; Papaioannou S; Meikle MC
Endocrinology; 1998 Apr; 139(4):1564-72. PubMed ID: 9528935
[TBL] [Abstract][Full Text] [Related]
27. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
28. Osteoblast function in myeloma.
Roodman GD
Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285
[TBL] [Abstract][Full Text] [Related]
29. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
30. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
31. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
32. Stimulatory effect of insulin-like growth factor binding protein-5 on mouse osteoclast formation and osteoclastic bone-resorbing activity.
Kanatani M; Sugimoto T; Nishiyama K; Chihara K
J Bone Miner Res; 2000 May; 15(5):902-10. PubMed ID: 10804020
[TBL] [Abstract][Full Text] [Related]
33. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
34. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
35. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
36. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
37. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
39. Morphology and biochemistry of bone remodeling: possible control by vitamin D, parathyroid hormone, and other substances.
Huffer WE
Lab Invest; 1988 Oct; 59(4):418-42. PubMed ID: 3050272
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis of myeloma bone disease.
Roodman GD
Leukemia; 2009 Mar; 23(3):435-41. PubMed ID: 19039321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
